Acta Neuropathol

1. DE BOER A, van den Bosch AMR, Mekkes NJ, Fransen NL, et al
   Disentangling the heterogeneity of multiple sclerosis through identification of independent neuropathological dimensions.
   Acta Neuropathol. 2024;147:90.
   

   >> Share

   
   

   
   Ann Neurol

2. CORTESE R, Battaglini M, Prados F, Gentile G, et al
   Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
   Ann Neurol. 2024 May 23. doi: 10.1002/ana.26951.
   

   >> Share

   
   

   
   Can J Neurol Sci

3. OH J, Bhan V, Traboulsee A, Morrow SA, et al
   Health Canada drug approval process: a barrier to personalized care in multiple sclerosis.
   Can J Neurol Sci. 2024 May 23:1-12. doi: 10.1017/cjn.2024.
   

   >> Share

   
   

   
   J Immunol

4. VEMULAWADA C, Renavikar PS, Crawford MP, Steward-Tharp S, et al
   Disruption of IFNgamma, GZMB, PRF1, or LYST Results in Reduced Suppressive Function in Human CD8+ T Cells.
   J Immunol. 2024;212:1722-1732.
   

   >> Share

   
   
5. FRANK C, Salapa HE, Allen KJH, Levin MC, et al
   Antibody-Mediated Depletion of Autoreactive T Lymphocytes through PD-1 Improves Disease Outcomes and Visualizes T Cell Activation in Experimental Autoimmune Encephalomyelitis.
   J Immunol. 2024 Apr 5:ji2300751. doi: 10.4049/jimmunol.2300751.
   

   >> Share

   
   

   
   J Neuroimmunol

6. SRIRAM S, Kim KW, Ljunggren-Rose A
   Targeted DeSUMOylation as a therapeutic strategy for multiple sclerosis.
   J Neuroimmunol. 2024;392:578371.
   

   >> Share

   
   
7. GELIBTER S, Saraceno L, Pirro F, Susani EL, et al
   As time goes by: Treatment challenges in elderly people with multiple sclerosis.
   J Neuroimmunol. 2024;391:578368.
   

   >> Share

   
   

   
   J Neurol

8. MONTEIRO I, Nicolella V, Fiorenza M, Novarella F, et al
   The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.
   J Neurol. 2024 May 23. doi: 10.1007/s00415-024-12434.
   

   >> Share

   
   

   
   J Neurol Neurosurg Psychiatry

9. NICHOLAS R, Tallantyre EC, Witts J, Marrie RA, et al
   Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales.
   J Neurol Neurosurg Psychiatry. 2024 May 23:jnnp-2024-333532.
   

   >> Share

   
   

   
   J Neurol Sci

10. SKARLIS C, Papadopoulos V, Raftopoulou S, Mavragani CP, et al
    Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    J Neurol Sci. 2024;461:123046.
    

    >> Share

    
    
11. JAKIMOVSKI D, Qureshi F, Ramanathan M, Jalaleddini K, et al
    Glial cell injury and atrophied lesion volume as measures of chronic multiple sclerosis inflammation.
    J Neurol Sci. 2024;461:123055.
    

    >> Share

    
    

    
    Mult Scler

12. AKBARIAN F, Rossi C, Costers L, D'hooghe MB, et al
    Stimulus-related modulation in the 1/f spectral slope suggests an impaired inhibition during a working memory task in people with multiple sclerosis.
    Mult Scler. 2024 May 20:13524585241253777. doi: 10.1177/13524585241253777.
    

    >> Share

    
    
13. MENG D, Sacco R, Disanto G, Widmer F, et al
    Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis.
    Mult Scler. 2024 May 20:13524585241250199. doi: 10.1177/13524585241250199.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share